A retrospective study of melanoma patients switching to ICI whilst deriving benefit (sDR, n = 37) or at progression (sPD, n = 37) on BRAF/MEK targeted therapy (TT), showed a trend towards survival benefit for the sDR group (median OS: 30.8 versus 14.1 months sPD, HR: 0.48). 136 In a pooled analysis of data from three pembrolizumab studies, patients with BRAF-mutant melanoma and prior TT had baseline characteristics with worse prognosis and worse tumour outcomes versus the TT
1
—
—